AstraZeneca PLC Gets Japan Boost with Cancer Drug Deal, Will Co-Promote Denosumab With Daiichi Sankyo, Inc.

AstraZeneca (AZN.L) is to co-promote Amgen's (AMGN.O) promising new drug denosumab in Japan as a treatment for bone cancer disorders alongside Daiichi Sankyo (4568.T), boosting its presence in the country.

Japan is a growing focus for Western drugmakers, who see good prospects in the country as more medicines originally developed for U.S. and European markets are introduced.

Back to news